Payment overview · 2025
General Payments
$192.80
7 reported records · 6 companies
Healthcare provider profile · identity verified
Tej Kokroo, MD
Allopathic & Osteopathic Physicians|Internal Medicine · LANGHORNE, PA · NPI 1437191798
Verified facts
What the public records show
CMS Open Payments records show Tej Kokroo, MD received $192.80 in general payments during 2025 across 7 reported records.
Otsuka America Pharmaceutical, Inc. accounted for 29.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Symbicort by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Nuedexta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $55.92 | 29.0% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $43.25 | 22.4% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $37.86 | 19.6% | 1 | 2025 |
| Bausch Health US, LLC | Unresolved — no canonical attribution shown | $22.65 | 11.8% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $18.66 | 9.7% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $14.46 | 7.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $149.55 | 6 |
| Education | $43.25 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $55.92 | 2 | 2025 |
Source payment records
|
|||||
| ENHERTU Normalized: enhertu |
Biological | AstraZeneca Pharmaceuticals LP | $43.25 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $37.86 | 1 | 2025 |
Source payment records
|
|||||
| WELLBUTRIN Normalized: wellbutrin |
Drug | Bausch Health US, LLC | $22.65 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $18.66 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $14.46 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 476 | 100 |
| Amlodipine Besylate | Amlodipine Besylate | 339 | 81 |
| Levothyroxine Sodium | Levothyroxine Sodium | 281 | 55 |
| Metoprolol Succinate | Metoprolol Succinate | 239 | 46 |
| Pantoprazole Sodium | Pantoprazole Sodium | 231 | 48 |
| Losartan Potassium | Losartan Potassium | 218 | 52 |
| Eliquis | Apixaban | 209 | 37 |
| Tamsulosin Hcl | Tamsulosin Hcl | 182 | 39 |
| Furosemide | Furosemide | 180 | 41 |
| Metformin Hcl | Metformin Hcl | 179 | 41 |
| Metoprolol Tartrate | Metoprolol Tartrate | 171 | 48 |
| Potassium Chloride | Potassium Chloride | 152 | 35 |
| Clopidogrel | Clopidogrel Bisulfate | 130 | 26 |
| Sertraline Hcl | Sertraline Hcl | 127 | 31 |
| Omeprazole | Omeprazole | 126 | 33 |
| Gabapentin | Gabapentin | 119 | 28 |
| Trazodone Hcl | Trazodone Hcl | 113 | 19 |
| Lisinopril | Lisinopril | 108 | 24 |
| Quetiapine Fumarate | Quetiapine Fumarate | 103 | 19 |
| Simvastatin | Simvastatin | 96 | 22 |
| Mirtazapine | Mirtazapine | 85 | 18 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 84 | 22 |
| Donepezil Hcl | Donepezil Hcl | 80 | 16 |
| Allopurinol | Allopurinol | 78 | 17 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 72 | 25 |
| Prednisone | Prednisone | 69 | 23 |
| Hydrochlorothiazide | Hydrochlorothiazide | 66 | 16 |
| Carvedilol | Carvedilol | 63 | 13 |
| Xarelto | Rivaroxaban | 59 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 55 | 20 |
| Myrbetriq | Mirabegron | 55 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 54 | suppressed |
| Risperidone | Risperidone | 52 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 51 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 51 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 51 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 45 | suppressed |
| Levetiracetam | Levetiracetam | 45 | suppressed |
| Spironolactone | Spironolactone | 44 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 43 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 43 | 11 |
| Celecoxib | Celecoxib | 41 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 40 | suppressed |
| Famotidine | Famotidine | 40 | suppressed |
| Atenolol | Atenolol | 38 | suppressed |
| Glipizide | Glipizide | 38 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 38 | suppressed |
| Azithromycin | Azithromycin | 37 | 18 |
| Entresto | Sacubitril/Valsartan | 37 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 36 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 35 | suppressed |
| Latanoprost | Latanoprost | 34 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 34 | 21 |
| Breo Ellipta | Fluticasone/Vilanterol | 33 | suppressed |
| Ezetimibe | Ezetimibe | 33 | suppressed |
| Glipizide Er | Glipizide | 32 | suppressed |
| Januvia | Sitagliptin Phosphate | 32 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 31 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 30 | suppressed |
| Levofloxacin | Levofloxacin | 30 | 18 |
| Sodium Chloride | 0.9 % Sodium Chloride | 30 | 13 |
| Farxiga | Dapagliflozin Propanediol | 29 | suppressed |
| Memantine Hcl | Memantine Hcl | 29 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 28 | suppressed |
| Repaglinide | Repaglinide | 27 | suppressed |
| Aripiprazole | Aripiprazole | 26 | suppressed |
| Bumetanide | Bumetanide | 26 | suppressed |
| Cephalexin | Cephalexin | 26 | 15 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 26 | 21 |
| Digoxin | Digoxin | 26 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 26 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 25 | suppressed |
| Sucralfate | Sucralfate | 24 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 24 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 23 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 23 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 22 | 14 |
| Flecainide Acetate | Flecainide Acetate | 22 | suppressed |
| Kerendia | Finerenone | 22 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 22 | 15 |
| Alendronate Sodium | Alendronate Sodium | 21 | suppressed |
| Colchicine | Colchicine | 21 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 21 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 20 | suppressed |
| Finasteride | Finasteride | 20 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 20 | suppressed |
| Nystatin | Nystatin | 20 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 20 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 20 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 19 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 19 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 19 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 19 | suppressed |
| Valsartan | Valsartan | 19 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 18 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 17 | suppressed |
| Loxapine | Loxapine Succinate | 17 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 17 | suppressed |
| Olanzapine | Olanzapine | 17 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 17 | 12 |
| Trulicity | Dulaglutide | 17 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 16 | 11 |
| Benazepril Hcl | Benazepril Hcl | 16 | suppressed |
| Fenofibrate | Fenofibrate | 15 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 15 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Rytary | Carbidopa/Levodopa | 14 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 13 | suppressed |
| Gemtesa | Vibegron | 13 | suppressed |
| Glimepiride | Glimepiride | 13 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 13 | suppressed |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Torsemide | Torsemide | 13 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 12 | 12 |
| Bethanechol Chloride | Bethanechol Chloride | 12 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 12 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Nystop | Nystatin | 12 | suppressed |
| Xifaxan | Rifaximin | 12 | suppressed |
| Amantadine | Amantadine Hcl | 11 | suppressed |
| Baclofen | Baclofen | 11 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 11 | suppressed |
| Budesonide | Budesonide | 11 | suppressed |
| Clozapine | Clozapine | 11 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 11 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 11 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 11 | suppressed |
| Lorazepam | Lorazepam | 11 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 11 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
| Rasagiline Mesylate | Rasagiline Mesylate | 11 | suppressed |
| Synthroid | Levothyroxine Sodium | 11 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $192.80 · 7 records | Otsuka America Pharmaceutical, Inc. | CAPLYTA, ENHERTU, REXULTI, TZIELD, WELLBUTRIN, ZORYVE | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error